240 related articles for article (PubMed ID: 21548602)
1. Elucidation of the Hsp90 C-terminal inhibitor binding site.
Matts RL; Dixit A; Peterson LB; Sun L; Voruganti S; Kalyanaraman P; Hartson SD; Verkhivker GM; Blagg BS
ACS Chem Biol; 2011 Aug; 6(8):800-7. PubMed ID: 21548602
[TBL] [Abstract][Full Text] [Related]
2. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
Donnelly A; Blagg BS
Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
[TBL] [Abstract][Full Text] [Related]
3. Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization.
Allan RK; Mok D; Ward BK; Ratajczak T
J Biol Chem; 2006 Mar; 281(11):7161-71. PubMed ID: 16421106
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of heat shock protein 90 chaperone function through binding of a novobiocin analog KU-32.
Chatterjee BK; Jayaraj A; Kumar V; Blagg B; Davis RE; Jayaram B; Deep S; Chaudhuri TK
J Biol Chem; 2019 Apr; 294(16):6450-6467. PubMed ID: 30792306
[TBL] [Abstract][Full Text] [Related]
5. Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions.
Yun BG; Huang W; Leach N; Hartson SD; Matts RL
Biochemistry; 2004 Jun; 43(25):8217-29. PubMed ID: 15209518
[TBL] [Abstract][Full Text] [Related]
6. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone.
Marcu MG; Chadli A; Bouhouche I; Catelli M; Neckers LM
J Biol Chem; 2000 Nov; 275(47):37181-6. PubMed ID: 10945979
[TBL] [Abstract][Full Text] [Related]
7. Revisiting silibinin as a novobiocin-like Hsp90 C-terminal inhibitor: Computational modeling and experimental validation.
Cuyàs E; Verdura S; Micol V; Joven J; Bosch-Barrera J; Encinar JA; Menendez JA
Food Chem Toxicol; 2019 Oct; 132():110645. PubMed ID: 31254591
[TBL] [Abstract][Full Text] [Related]
8. A hydrophobic segment within the C-terminal domain is essential for both client-binding and dimer formation of the HSP90-family molecular chaperone.
Yamada S; Ono T; Mizuno A; Nemoto TK
Eur J Biochem; 2003 Jan; 270(1):146-54. PubMed ID: 12492485
[TBL] [Abstract][Full Text] [Related]
9. Mutations in the Hsp90 N Domain Identify a Site that Controls Dimer Opening and Expand Human Hsp90α Function in Yeast.
Reidy M; Masison DC
J Mol Biol; 2020 Jul; 432(16):4673-4689. PubMed ID: 32565117
[TBL] [Abstract][Full Text] [Related]
10. A Nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket.
Söti C; Rácz A; Csermely P
J Biol Chem; 2002 Mar; 277(9):7066-75. PubMed ID: 11751878
[TBL] [Abstract][Full Text] [Related]
11. Liberation of the intramolecular interaction as the mechanism of heat-induced activation of HSP90 molecular chaperone.
Tanaka E; Nemoto TK; Ono T
Eur J Biochem; 2001 Oct; 268(20):5270-7. PubMed ID: 11606188
[TBL] [Abstract][Full Text] [Related]
12. Structural studies on the co-chaperone Hop and its complexes with Hsp90.
Onuoha SC; Coulstock ET; Grossmann JG; Jackson SE
J Mol Biol; 2008 Jun; 379(4):732-44. PubMed ID: 18485364
[TBL] [Abstract][Full Text] [Related]
13. The crystal structure of the carboxy-terminal dimerization domain of htpG, the Escherichia coli Hsp90, reveals a potential substrate binding site.
Harris SF; Shiau AK; Agard DA
Structure; 2004 Jun; 12(6):1087-97. PubMed ID: 15274928
[TBL] [Abstract][Full Text] [Related]
14. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins.
Marcu MG; Schulte TW; Neckers L
J Natl Cancer Inst; 2000 Feb; 92(3):242-8. PubMed ID: 10655441
[TBL] [Abstract][Full Text] [Related]
15. Substrate-binding characteristics of proteins in the 90 kDa heat shock protein family.
Nemoto TK; Ono T; Tanaka K
Biochem J; 2001 Mar; 354(Pt 3):663-70. PubMed ID: 11237871
[TBL] [Abstract][Full Text] [Related]
16. Exploiting conformational dynamics in drug discovery: design of C-terminal inhibitors of Hsp90 with improved activities.
Moroni E; Zhao H; Blagg BS; Colombo G
J Chem Inf Model; 2014 Jan; 54(1):195-208. PubMed ID: 24397468
[TBL] [Abstract][Full Text] [Related]
17. Domain-domain interactions of HtpG, an Escherichia coli homologue of eukaryotic HSP90 molecular chaperone.
Nemoto TK; Ono T; Kobayakawa T; Tanaka E; Baba TT; Tanaka K; Takagi T; Gotoh T
Eur J Biochem; 2001 Oct; 268(20):5258-69. PubMed ID: 11606187
[TBL] [Abstract][Full Text] [Related]
18. Structures of the N-terminal and middle domains of E. coli Hsp90 and conformation changes upon ADP binding.
Huai Q; Wang H; Liu Y; Kim HY; Toft D; Ke H
Structure; 2005 Apr; 13(4):579-90. PubMed ID: 15837196
[TBL] [Abstract][Full Text] [Related]
19. Identifying a C-terminal ATP binding sites-based novel Hsp90-Inhibitor in silico: a plausible therapeutic approach in Alzheimer's disease.
Khalid S; Paul S
Med Hypotheses; 2014 Jul; 83(1):39-46. PubMed ID: 24785461
[TBL] [Abstract][Full Text] [Related]
20. Hsp90 inhibitors identified from a library of novobiocin analogues.
Yu XM; Shen G; Neckers L; Blake H; Holzbeierlein J; Cronk B; Blagg BS
J Am Chem Soc; 2005 Sep; 127(37):12778-9. PubMed ID: 16159253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
